(Q38941593)

English

The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Tae-Gul Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Eun-Hui Jeong

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Seo Yun Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Hye-Ryoun Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Cheol Hyeon Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

26 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

2717-2729

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Treatment of non-small-cell lung cancer with erlotinib or gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Histone deacetylases, transcriptional control, and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Lysine acetylation: codified crosstalk with other posttranslational modifications

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Acetylation and deacetylation of non-histone proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Substrate and functional diversity of lysine acetylation revealed by a proteomics survey

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Epigenetic therapy of cancer: past, present and future

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Histone deacetylase inhibitors: discovery and development as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Translating the Histone Code

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Autophagic and apoptotic effects of HDAC inhibitors on cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Acetylation: a novel link between double-strand break repair and autophagy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Autophagy in yeast: a review of the molecular machinery

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Methods in mammalian autophagy research

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

The morphology of various types of cell death in prenatal tissues

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Autophagy as a cell death and tumor suppressor mechanism

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Potential therapeutic applications of autophagy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Self-eating and self-killing: crosstalk between autophagy and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Life and death partners: apoptosis, autophagy and the cross-talk between them

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Regulation of autophagy in mammals and its interplay with apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29320

21 January 2018

Identifiers

10.1002/IJC.29320

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

release_btdiakx67jdono64spc4nfrdfi

1 reference

https://api.fatcat.wiki/v0/release/btdiakx67jdono64spc4nfrdfi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38941593&oldid=1966821480"